FeedVoices: PAT Answers
On-demand Data Access and Analytics Enable Decisions for Process Excellence
Critical to any PAT effort is having a single point of easy, on-demand access to all relevant data, in a context that’s meaningful to diverse groups of users. But data must be presented in a way that facilitates the identification and understanding of cause-and-effect relationships. Justin Neway, CSO and EVP of Aegis Analytics, talks about the issues and what they mean for PAT-related IT.
PharmaManufacturing.com
By Justin O. Neway, Ph.D., EVP and Chief Science Officer, Aegis Analytical Corp.
 |
When looking closely at the role that integrated on-demand data access and analytics play in process improvement, two findings from the study become very relevant: 1) companies with strong manufacturing IT foundations perform better overall and 2) manufacturing decisions are often best initiated and implemented by those closest to the work.
At the intersection of IT and manufacturing decisions lies an important section of the FDA’s PAT Guideline for process improvement, which points to the value of continuous learning that comes from the analysis of process data when coupled with systems that support the acquisition of knowledge from that data:
In fact, the data to which the FDA refers comes not only from process instruments making real-time measurements on the current batch, but also from off-line measurements of the current batch as well as on-line and off-line measurements of previous batches. All these data from the current and previous batches are essential components of the knowledge base that can be tapped by manufacturers – across multiple levels of an organization – to optimize process development and full-scale operations.
Furthermore, these data are fragmented because they have accumulated in the operational data stores of many different systems, as well as paper records. These systems have evolved to serve the needs of groups of professionals with training in quality, engineering, operations, technical support, biology, chemistry, etc. Often these groups rely on others with IT skills to get their data for them. This causes delays that interfere with their effectiveness in developing the understanding of cause-and-effect relationships needed to reduce variability and increase process predictability. These realities must be taken into account in the process of “knowledge acquisition” to which the FDA has referred.
In addition to PAT and quality by design, there are many initiatives under way that share the goal of reducing the variability, cost and risks of life science manufacturing processes. At several points along the way they all depend fundamentally on identifying cause-and-effect relationships among process parameters and using this process understanding to improve process control.
Thus, one of the most critical aspects of many process improvement initiatives is a single point of easy, on-demand access to all the relevant data (including paper-based data) in a context meaningful to diverse groups of users and fully integrated with a collaborative, graphical data analysis and reporting environment for identifying and understanding cause-and-effect relationships in the process data.
The different data types must be easily accessible in a way that automatically accounts for their different formats and naming conventions, as well as their intra- and inter-batch genealogies. The access method must let users move directly into identifying and understanding the cause-and-effect relationships between Critical Process Parameters and Critical Quality Attributes without spending excessive amounts of time on programming tasks and manually collecting and cleaning up data.
Manufacturing IT solutions that can provide collaborative investigational analyses of cause-and-effect relationships help involve those closest to the work in manufacturing decisions – especially if systems are built for users who think in process terms more easily than in IT terms. Such solutions enable a collaborative team to span process development and manufacturing and move well beyond simple logistical and organizational improvements based on descriptive analysis to science-based process understanding and control based on investigational analysis.
Thus, process excellence and quality by design become practical realities only when the barriers to easily accessing and working with all the process data together are removed, and the team can spend its time instead on productive science-based collaboration that will satisfy not only the FDA, but also the many pharmaceutical executives concerned with lowering that $50 billion a year figure prior to Macher and Nickerson’s next benchmark study.
About the Author
Justin Neway, Ph.D., is executive vice president and chief science officer at Aegis Analytical Corp. He has more than 25 years of experience in pharmaceutical and biotechnological manufacturing, and in the development and application of software solutions for quality, compliance and operational efficiency in life science manufacturing. He can be reached at jneway@aegiscorp.com.
References
- Jeffrey Macher and Jackson Nickerson. 2006. Benchmarking Report on Pharmaceutical Manufacturing. October. (see http://faculty.msb.edu/jtm4/PMRP%20results/)
- U.S. Food and Drug Administration. 2004. PAT - A Framework for Innovative Pharmaceutical Manufacturing and Quality Assurance. Pharmaceutical CGMPs, September: 1-21.
More Voices
On-demand Data Access and Analytics Enable Decisions for Process Excellence
12/06/2006
Critical to any PAT effort is having a single point of easy, on-demand access to all relevant data, in a context that’s meaningful to diverse groups of users. But data must be presented in a way that facilitates the identification and understanding of cause-and-effect relationships. Justin Neway, CSO and EVP of Aegis Analytics, talks about the issues and what they mean for PAT-related IT.
Therapeutic Dose: Avoiding the “Cool Hand Luke” Effect
08/25/2006
Isolation and too narrow a focus limits possibilities — for your career and life, your organization, and the industry. Sure, you may be doing your job right, but are you doing the right job?
PAT in Perspective: Drugs Are Not Potato Chips
07/27/2006
Although PAT and technologies like NIR are important, there still are things that they cannot do, concedes NIR expert Emil Ciurczak. Are advocates within the industry suspending rational and much needed skepticism, he asks, when they talk about eliminating final product stability testing altogether?
Silencing the cGMP Priesthood
07/06/2006
cGMPS are essential, but when cGMP dogma triumphs over common sense and prevents innovation, we’re all in trouble, says NIR expert and pharmaceutical industry consultant Emil Ciurczak. He offers some tips for drawing the line between compliance and absurdity.
PAT in Perspective: Are We Being Spoiled by Success and the Internet?
06/27/2006
NIR expert Emil Ciurczak thinks prosperity and the Internet are making today's graduates far too complacent and out of touch for their own good. Networking and professional societies are at risk, he says, and drug manufacturing will be worse off for it.
PAT in Perspective: Do We Need Final Release Tests with PAT?
06/01/2006
NIR expert Emil Ciurczak asks whether PAT will eliminate the need for traditional USP product release tests…and concludes that they’re still essential as a reference method, and important in minimizing liability.
PAT in Perspective: “One Size Fits All” Software May Not Fit PAT
04/27/2006
Excel, with its rounding errors, is a prime example of software written without the input of “science-types.”
PAT in Perspective: Give Credit Where Credit is Due
03/24/2006
PAT and analytical services don’t always mix, as PAT columnist Emil Ciurczak relates. His advice: Don’t allow your PAT group to become a stepchild. Ensure that it receives credit for PAT-based improvements.
Urban Legends and Misconceptions
03/01/2006
A successful industry means job security for both FDA and instrument vendors. They are on your side; talk with them. Don’t rely on “word of mouth” to make decisions about PAT.
PAT in Perspective: Headcount and PAT—Fact and Fiction
01/24/2006
Attention, corporate bean counters: PAT is not a magic bullet for reducing QC headcounts. In fact, it may require hiring more people, but the efforts will pay off in improved efficiencies and lower costs.
PAT in Perspective: Estimate PAT’s Real Costs
12/20/2005
Don’t be “penny-wise but pound-foolish” during early planning and budgeting stages, and never base decisions on equipment sticker prices without considering savings in time to market.
PAT in Perspective: To Outsource or Not to Outsource . . .
11/22/2005
A consultant ponders the question, as it relates to NIR and pharmaceutical PAT projects that require a high level of hard-to-find technical expertise.
PAT in Perspective: Preaching to the Wrong Choir
10/27/2005
Last year at the IFPAC conference, NIR guru Emil Ciurczak bemoaned the fact that PAT was being promoted by geeks for geeks. Now, however, he notes that an upcoming summit may lead the charge toward a new emphasis on convincing corporate and financial managers that PAT simply makes good business sense.
Plug and Play PAT, Anyone?
07/28/2005
A common user interface, and “out of the box” software will be essential to driving PAT in the pharmaceutical industry, say Pfizer’s control and IT experts Velumani Pillai and Martin Warman. They’re developing a template for IT requirements and seek input from vendors and other users.
Less is More in API Process Development
06/22/2005
API manufacturers in India and China have grasped the need for simplicity, while U.S. process chemists continue along their costly and complex path. Girish Malhotra shares recommendations for improved API process development.
PAT Success and Speed Hinge on Data Mining
06/01/2005
Not only data mining but metadata must be considered closely, by a cross-functional team representing all users of that data.
PAT Takes Manhattan — and San Juan
04/29/2005
April’s Induniv conference in San Juan and Interphex in New York City focused on PAT to an unprecedented degree.
Companies Invited to Take Part in a New Proposed Engineering Research Center
04/29/2005
It’s not too soon to get involved in a new Engineering Research Center proposed by Rutgers, Purdue, NJIT and the University of Puerto Rico (Mayaguez). In this article, Rutgers University’s Holly Crawford and Fernando J. Muzzio describe the effort and how corporate involvement early on will help. A meeting is scheduled for May.
Staffing, Training and Validation Are Critical to PAT
03/31/2005
FDA’s involvement has convinced pharma to embrace PAT, but new recruitment and validation issues have arisen as PAT moves into its next phase.
PAT for Biopharma Slow to Take
03/31/2005
Weak FDA support and a dearth of adequate sensor technology are holding back adoption of PAT in biopharmaceutical manufacturing, says Xcellerex President Galliher.
Moving Toward a Proactive Decision System
03/31/2005
In his plenary speech at IFPAC 2005, FDA's Ajaz Hussain mapped out a "proactive journey" to pharmaceutical quality, based on PAT, science of design, and quality systems. Begin your journey now.
Rick Cooley Puts PAT in Perspective
02/24/2005
A pioneer offers his perspectives on PAT and where it’s heading and reminisces about his 23+ years leading Eli Lilly’s process analytics program. His advice: Remember that PAT won’t magically lead to headcount reduction; it isn’t always easy to do, and you can (and should) start small! Before starting a new position as North American manager of process analytics with the chromatography vendor Dionex, he shared his views with Editor in Chief Agnes Shanley.
From the Editor: Operator Error: Does the Industry Have ADD?
01/27/2005
Human error is something that drug manufacturers can no longer ignore, as a recent drug recall shows.
Huygens Probe and PAT: Exploring a New World
01/26/2005
New worlds demand a new approach to measurement and data collection.
To Bridge the PAT Divide, Stop Preaching to the Choir
12/28/2004
Advocates need to communicate the benefits of PAT more forcefully to senior management.
How Capable Are Your Processes? Do You Know?
12/23/2004
The industry needs to understand its manufacturing processes if it is to transform them and better serve its ultimate consumer, the patient, asserts G.K. Raju, CEO of Light Pharma, Inc.